We are in the midst of a scientific renaissance in neurodegeneration, driven by growing evidence of overarching biological processes that drive neurodegenerative disorders.
Our ambition at Janssen is to become a leader in neurodegeneration. We are working to develop innovations for a diverse range of patients, from large, clinically diverse populations to rare diseases within which genetic markers may further development of therapies for other idiopathic diseases.
This work begins with R&D, where we have potentially transformational early science in Alzheimer’s disease (AD) and Parkinson’s disease. For example, in AD, we are utilizing plasma biomarkers in our trials to detect central amyloid positivity and tau status.
The recent launch of our disease modifying therapy in multiple sclerosis was also a critical step toward our re-entry into neurology and, most importantly, offers patients a meaningful choice for treatment backed by nearly a decade of research.